Drugs / Gastrografin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GASTROGRAFIN | — | 1958-01-17 | fda.gov ↗ |
Trials 10 · a red edge is where a trial was stopped
1956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02784093 | Apr 2015 → May 2017 | intestinal impaction | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03573921 | Sep 2019 → Dec 2022 | intestinal obstruction | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 2/3 | NCT01648972 | Sep 2012 → Jul 2014 | ileus | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06182319 | Jan 2024 → Dec 2025 overdue | intestinal obstruction | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 3 | NCT05726097 | Feb → Oct 2023 | colorectal cancer, inflammatory bowel disease, polyp of colon | Region Skane | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03334578 | Aug 2018 → Dec 2020 | gastroschisis, intestinal obstruction | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| Phase 4 | NCT01440712 | Dec 2011 → Nov 2013 | ileus | Hospital Universitari de Bellvitge | Completed | No outcome recorded |
| Phase 4 | NCT00601809 | Sep 2003 → Nov 2006 | intestinal obstruction | University of Bologna | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02481219 | May 2015 → Jan 2016 | colorectal cancer | Medtronic - MITG | Completed | No outcome recorded |
| — | NCT03642288 | Apr 2014 → Jun 2018 | — | Jinling Hospital, China | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01515696 Comparator | Oct 2007 → Oct 2010 | meconium ileus | Nadja Haiden,MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02371655 Background | Oct 2015 → Dec 2016 | colonic neoplasm | University of Roma La Sapienza | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gastrografin | “Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination” NCT02371655 ↗12“Gastrografin is a water soluble contrast mediate that could act as an osmotic laxative.” NCT02784093 ↗ |
| Modality | Diagnostic / imaging agent | “The diagnostic and therapeutic role of water-soluble contrast medium (Gastrografin) in ASIO is still debated.” PMID 18688562 ↗ Oct 2008 |
| Route | Oral | “the study group (GG) received in addition a Gastrografin meal and follow-through study immediately.” PMID 18688562 ↗ Oct 2008 |